Review
Immunology
Xinyu Wang, Qian-Nan Jia, Mengyin Wu, Mingjuan Liu, Jun Li
Summary: This study conducted a bibliometric analysis to assess the global research trends and impact of publications related to melanoma and vaccine therapy. The results showed that melanoma and vaccine therapy have gained significant attention in the field of cancer immunotherapy, with increasing research output and citation impact. The United States, China, and their organizations are leading in terms of publication output, and collaborative research networks are prominent. Clinical trials evaluating the safety and efficacy of vaccination treatment in melanoma patients are the focus of research.
Article
Pharmacology & Pharmacy
Fatemeh Zahedipour, Parvin Zamani, Khadijeh Jamialahmadi, Mahmoud Reza Jaafari, Amirhossein Sahebkar
Summary: Angiogenesis plays a significant role in the metastasis and progression of melanoma. Vaccines targeting angiogenesis in melanoma, including specific immunotherapy, show promise in inducing strong anti-tumor immune responses by targeting genetically stable endothelial cells. Various types of vaccines, such as DNA, peptide, protein, dendritic cell-based, and endothelial cell vaccines, have been studied to target angiogenesis in melanoma for potential progress in developing effective treatments.
EUROPEAN JOURNAL OF PHARMACOLOGY
(2021)
Article
Medicine, Research & Experimental
Aviyah Peri, Erez Greenstein, Michal Alon, Joy A. Pai, Tamir Dingjan, Shlomit Reich-Zeliger, Eilon Barnea, Chaya Barbolin, Ronen Levy, Claudia Arnedo-Pac, Shelly Kalaora, Bareket Dassa, Ester Feldmesser, Ping Shang, Polina Greenberg, Yishai Levin, Gil Benedek, Mitchell P. Levesque, David J. Adams, Michal Lotem, James S. Wilmott, Richard A. Scolyer, Goeran B. Joensson, Arie Admon, Steven A. Rosenberg, Cyrille J. Cohen, Masha Y. Niv, Nuria Lopez-Bigas, Ansuman T. Satpathy, Nir Friedman, Yardena Samuels
Summary: The study identified an immunogenic neoantigen applicable to 3% of melanoma patients, showing its endogenous presentation and natural immunogenicity. Analysis further revealed the diversity of neoantigen-specific clones and their response and phenotypic characteristics in combating melanoma.
JOURNAL OF CLINICAL INVESTIGATION
(2021)
Article
Immunology
Seyedeh Alia Moosavian, Maryam Hashemi, Leila Etemad, Sara Daneshmand, Zahra Salmasi
Summary: Exosomes play a crucial role in early diagnosis and various functions related to angiogenesis, immune modulation, migration, metastasis, chemotherapy resistance, and tumor progression in melanoma. Natural exosomes have the potential to be utilized as nanocarriers and cancer vaccines for more efficient cancer treatment in the era of novel bioengineering and immunotherapy approaches.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2022)
Article
Oncology
Gil Awada, Yanina Jansen, Julia Katharina Schwarze, Jens Tijtgat, Lennert Hellinckx, Odrade Gondry, Sim Vermeulen, Sarah Warren, Kelly Schats, Pieter-Jan van Dam, Mark Kockx, Marleen Keyaerts, Hendrik Everaert, Teofila Seremet, Anne Rogiers, Bart Neyns
Summary: Pembrolizumab improves survival in advanced melanoma patients by targeting programmed cell death 1. This study analyzed baseline clinical characteristics and gene expression profiling in relation to survival in patients treated with pembrolizumab, finding organ function and systemic inflammatory/immunologic status to be key predictors of survival. Novel biomarkers such as baseline DNA mutations and total metabolic tumor volume were also identified as predictive factors.
Review
Dermatology
P. Lau, M. Shen, F. Ma, Y. Chen, J. Zhang, J. Su, X. Chen, H. Liu
Summary: This study compared and ranked various immunotherapeutic strategies for melanoma, showing that allogeneic tumor cell vaccines with immunotherapy adjuvants, peptide-based vaccines with immunotherapy adjuvants, and standard therapy were more effective than peptide vaccines. Safety-wise, all treatments were inferior to allogeneic tumor cell vaccines, except when combined with chemotherapy. Peptide vaccines with immunotherapy adjuvants were associated with increased risk of adverse events compared to allogeneic tumor cell vaccines with immunotherapy adjuvants.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
(2021)
Article
Oncology
Jiaheng Xie, Mengmeng Ou, Pan Yu, Dan Wu, Qikai Tang, Yuan Cao, Jing Hang, Lu Yin, Tinghong Xiang, Ming Wang, Jingping Shi
Summary: This study aims to identify potential tumor antigens for melanoma vaccine development and identify different immune subtypes through analyzing transcriptional data and clinical information. The results show that several potential tumor antigens have been identified, and melanoma patients can be divided into two immune subtypes with significant differences in tumor immunity. Cell function experiments further validate the important role of IDO1 in melanoma.
Article
Oncology
Haiqin Ping, Wenjun Yu, Xiaoming Gong, Xin Tong, Cheyu Lin, Zhaojun Chen, Caiyun Cai, Kai Guo, Hengning Ke
Summary: This study identifies potential tumor antigens in melanoma that could be targeted for mRNA vaccines and identifies two immune subtypes of melanoma with different clinical features and immune landscapes.
INVESTIGATIONAL NEW DRUGS
(2022)
Article
Immunology
Richard Harris
Summary: This study analyzed a (population weighted) sample of 4533 responses to a household survey conducted in March 2021 on the impact of COVID-19 on residents in the North East of England. The results showed that factors such as age, socioeconomic status, ethnicity, and religious beliefs were important in determining willingness to undergo testing, self-isolation, and vaccine hesitancy. Future vaccination and 'track and trace' programs may need to consider these factors for better effectiveness.
Article
Biotechnology & Applied Microbiology
Qiliang Yin, Na Zhao, Ying Chang, Mingxin Dong, Meng Xu, Wenyue Xu, Hao-Fan Jin, Wensen Liu, Na Xu
Summary: Melanoma stem cells (MSCs)-based vaccine strategies have shown promising results in treating melanoma by inducing specific anti-tumor immunity and targeting cancer stem-like cells. A novel MSC vaccine was developed to activate CD8(+)T cells specifically against melanoma stem cells. It was found that the MSC vaccine promoted DCs maturation, activated CD8(+)T cells, suppressed the expression of immune checkpoint proteins, and increased the expression of immune molecules associated with anti-tumor responses. The vaccine's specific targeted killing effect inhibited melanoma growth and metastasis.
HUMAN VACCINES & IMMUNOTHERAPEUTICS
(2023)
Article
Oncology
Timothy J. Vreeland, Guy T. Clifton, Diane F. Hale, Robert C. Chick, Annelies T. Hickerson, Jessica L. Cindass, Alexandra M. Adams, Phillip M. Kemp Bohan, Robert H. I. Andtbacka, Adam C. Berger, James W. Jakub, Jeffrey J. Sussman, Alicia M. Terando, Thomas Wagner, George E. Peoples, Mark B. Faries
Summary: This study demonstrates that the TLPLDC vaccine is well-tolerated and improves disease-free survival in patients with resected stage III/IV melanoma, indicating potential benefits for preventing future recurrence in patients who do not recur early.
ANNALS OF SURGICAL ONCOLOGY
(2021)
Article
Engineering, Biomedical
Nuria Lafuente-Gomez, Irene de Lazaro, Monica Dhanjani, David Garcia-Soriano, Miguel C. Sobral, Gorka Salas, David J. Mooney, Alvaro Somoza
Summary: A novel immunotherapy based on magnet nanoparticles is described in this study, which significantly enhances immune response and combats melanoma cells. Covalently modified nanoparticles exhibit a more potent and sustained immune response in vivo.
MATERIALS TODAY BIO
(2023)
Article
Biochemistry & Molecular Biology
Anggit Listyacahyani Sunarwidhi, Ari Hernawan, Andri Frediansyah, Sri Widyastuti, Ni Wayan Riyani Martyasari, Angga Susmana Abidin, Hasriaton Padmi, Ervina Handayani, Ni Wayan Putri Utami, Farreh Alan Maulana, Muhammad Syach Maulad Ichfa, Eka Sunarwidhi Prasedya
Summary: This study investigated the effect of two extraction methods on ethanol extracts of Indonesian brown algae. The ultrasonic-assisted extraction (UAE) method had a higher yield and total phenolic content (TPC), and contained more lipophilic compounds. The total flavonoid content (TFC) did not differ significantly between the two methods. Further analysis showed that TPC, rather than TFC, was correlated with the antioxidant activities and cytotoxicity of the extracts. This suggests that UAE could be a preferred method for extracting natural anti-melanogenic agents from brown algae.
Article
Chemistry, Multidisciplinary
Marisa E. Aikins, You Qin, Hannah E. Dobson, Alireza Hassani Najafabadi, Kexing Lyu, Yao Xu, Ying Xin, Anna Schwendeman, Max S. Wicha, Alfred E. Chang, Qiao Li, James J. Moon
Summary: One major obstacle in cancer treatment is the presence of cancer stem cells (CSCs), which are resistant to traditional therapies and contribute to metastasis and relapse. In this study, a therapeutic vaccine targeting CSCs in melanoma was developed and shown to effectively reduce tumor growth and improve survival. The vaccine stimulated strong T cell responses against CSC-associated antigens and promoted infiltration of CD8+ T cells into tumors, while reducing the frequency of CSCs. This approach represents a safe and cost-effective strategy for targeting and eliminating CSCs in melanoma and other types of cancer.
JOURNAL OF CONTROLLED RELEASE
(2022)
Review
Immunology
Clio Bilotta, Giulio Perrone, Valeria Adelfio, Giovanni Francesco Spatola, Maria Laura Uzzo, Antonina Argo, Stefania Zerbo
Summary: This study analyzed cases of thrombosis after COVID-19 vaccinations to identify patients' features, potential pathophysiological mechanisms, timing of appearance of the adverse events, and other critical issues. The study found different characteristics in patients who experienced adverse events after receiving Pfizer, Moderna, and AstraZeneca vaccines. Further research is needed to better understand the pathophysiological mechanisms of vaccine-induced thrombotic thrombocytopenia (VITT).
FRONTIERS IN IMMUNOLOGY
(2021)